Rosetta Reports First Payment From the UK's NHS for the Rosetta Cancer Origin Test(TM); Halozyme To Present At The Credit Suisse Healthcare Conference Print E-mail
By Staff and Wire Reports   
Wednesday, 06 November 2013 19:59
Below is a look at some of the headlines for companies that made news in the healthcare sector on November 6, 2013.
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the National Health Service (NHS) of the United Kingdom (UK), the world's largest publicly-funded health service, has made its first payment to the Company for use of the Rosetta Cancer Origin Test™ on a British citizen. The accurate identification of the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP) is important in guiding clinician treatment decisions to maximize patient outcomes.

John Bridgewater, M.D., University College London Hospital, UCL Cancer Center, one of the UK's leading experts on CUP and the patient's treating physician, noted, "Cancers of unknown primary are a high priority in the UK health system as evidenced by the requirements to have CUP Clinics at all Cancer Centers. We are very pleased that the NHS has understood the importance of the Cancer Origin Test to better define the best therapeutic choices in these cases, and expect to continue to improve the care of our patients through utilization of this test."

"We are very pleased with this payment from the NHS, for although it does not signify a universal policy decision, it does represent a pathway for individual patients to gain access to this important test and shows that the NHS recognizes the clinical value of our Cancer Origin Test, in conjunction with the treating oncologist's assessment," stated E. Robert Wassman, M.D., Rosetta's Chief Medical Officer.



=======================



Halozyme Therapeutics, Inc. (NASDAQ: HALO)
will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 13, 2013 at 5:30 p.m. ET/2:30 p.m. PT.Gregory I. Frost, President and Chief Executive Officer, Halozyme Therapeutics, will provide a corporate overview.

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.




Also Wednesday:




Abiomed, Inc. (Nasdaq:ABMD)
, a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2014 revenue of $44.3 million, up 19% compared to revenue of $37.4 million in the same period of fiscal 2013, and a second quarter fiscal 2014 GAAP net income of $1.1 million or $0.03 per diluted share, compared to $5.5 million or $0.13 per diluted share in the prior year period.

Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Amarin Corporation plc (NASDAQ: AMRN) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey.  

Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS)
, a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced the appointment of David A. Lowe, PhD to its Board of Directors.

Aurinia Pharmaceuticals Inc. (TSX-V:AUP)
today announced the appointment of Stephen W. Zaruby as the Company's President and Chief Executive Officer.

Baxano Surgical, Inc. (Nasdaq:BAXS),
a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced its financial results for the third quarter ended September 30, 2013.

BG Medicine, Inc. (Nasdaq:BGMD)
, the developer of the BGM Galectin-3 Test, today reported financial results for the third quarter of 2013.

BG Medicine, Inc. (Nasdaq:BGMD)
, the developer of the BGM Galectin-3 Test and SilverStaff Clinical Laboratories, Inc. today announced that SilverStaff will be offering galectin-3 testing services to its laboratory customers and physicians.

Cancer Genetics, Inc. (Nasdaq:CGIX)
, a DNA based diagnostics company focused on developing genomic-based, oncology tests and services, received a formal Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application covering a panel of probes for use in its proprietary methods for the detection and differentiation of kidney cancer.

ChemoCentryx, Inc. (Nasdaq:CCXI)
, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 2013 Credit Suisse Annual Health Care Conference on Wednesday, November 13, 2013, at 11:00 a.m. Mountain Time at the The Phoenician in Scottsdale, AZ.

Cleveland BioLabs, Inc. (Nasdaq:CBLI)
today reported financial results and development progress for the third quarter and nine-month periods ended September 30, 2013.

Coronado Biosciences, Inc. (Nasdaq:CNDO)
, a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the appointment of Kevin Horgan, M.D., as its Chief Medical Officer.

Curis, Inc. (Nasdaq:CRIS)
, an oncology-focused company seeking to develop novel, targeted drug candidates for the treatment of human cancers, today provided an update on the Phase 1 clinical trial of its oral inhibitor of apoptosis (IAP) antagonist, CUDC-427 and reported its financial results for the third quarter ended September 30, 2013.

Cutera, Inc. (Nasdaq:CUTR)
, a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, announced today that Kevin Connors, the Company's President and CEO, will be presenting at the following three investor conferences:  The Canaccord Genuity Medical Technologies & Diagnostics Forum to be held on Thursday, November 14 at the Westin Grand Central in New York, NY. Cutera's presentation will take place at 2:30 PM Eastern Time.

Endocyte, Inc. (Nasdaq:ECYT)
, a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that Ron Ellis, president and CEO of Endocyte, will present at the 2013 Credit Suisse Healthcare Conference on Wednesday, Nov.13, at 8:30 a.m. MST.

The Ensign Group, Inc. (Nasdaq:ENSG)
, the parent company of the Ensign(TM) group of skilled nursing, rehabilitative care services, assisted living, home health and hospice care and urgent care companies, announced today that it expects to issue its third quarter 2013 financial results on Thursday, November 7, 2013.

Fate Therapeutics, Inc. (Nasdaq:FATE)
, a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 13, 2013, at 5:00 p.m. EST to report its third quarter 2013 financial results and provide a corporate update.

Galena Biopharma (Nasdaq:GALE)
, a biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today reported its financial results for the three and nine months ended September 30, 2013 and provided a business update.

Halozyme Therapeutics, Inc. (NASDAQ: HALO)
will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 13, 2013 at 5:30 p.m. ET/2:30 p.m. PT.Gregory I. Frost, President and Chief Executive Officer, Halozyme Therapeutics, will provide a corporate overview.

Hyperion Therapeutics, Inc. (Nasdaq:HPTX)
today announced that it will host a teleconference and webcast with management to provide a general business overview, as well as to discuss its third quarter 2013 financial results on Tuesday, November 12, 2013 at 4:30 p.m. ET (1:30 p.m. PT).

IPC The Hospitalist Company, Inc. (Nasdaq:IPCM)
, a leading national hospitalist physician group practice, today announced that Adam Singer, M.D., chairman and chief executive officer, and Rick Kline, chief financial officer, are scheduled to present at the 2013 Credit Suisse Annual Healthcare Conference at The Phoenician in Scottsdale, Arizona.

Health Insurance Innovations, Inc. (Nasdaq:HIIQ)
, today announced that Mike Kosloske, Chief Executive Officer, and Jim Dietz, SVP of Finance and Business Development, of HII will present an overview of the company Wednesday, November 13th at 1:30 pm Mountain Time at the Credit Suisse 2013 Healthcare Conference.

LDR Holding Corporation (Nasdaq:LDRH)
, a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, today reported its financial results for the third quarter and nine months ended September 30, 2013.

LeMaitre Vascular, Inc. (Nasdaq:LMAT)
, a provider of peripheral vascular devices and implants, announced today that it will webcast its investor and analyst days to be held on November 12th and 13th. These events will be hosted and webcast live from two locations:  Tuesday, November 12, 9:30 AM to 1:00 PM EST, Corporate Headquarters, Burlington, MA, and Wednesday, November 13, 9:30 AM to 12:30 PM PST, One Market Restaurant, San Francisco, CA

LHC Group, Inc. (Nasdaq:LHCG)
, a national provider of post-acute care services, today announced its financial results for the three months and nine months ended September 30, 2013.

MELA Sciences, Inc. (Nasdaq:MELA)
, the medical device company that has developed and is commercializing MelaFind®, an optical diagnostic device using proprietary technology that enables dermatologists to "see" below the surface of a patient's skin to aid in the diagnosis of melanoma, today announced financial results for the third quarter ended September 30, 2013.

MELA Sciences, Inc. (Nasdaq:MELA)
, the medical device company that has developed and is commercializing MelaFind®, an optical diagnostic device using proprietary technology that enables dermatologists to "see" below the surface of a patient's skin to aid in the diagnosis of melanoma, today announced that the Company has appointed Rose Crane as its President and Chief Executive Officer and a director, effective as of November 11, 2013.

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA)
, a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentations at two upcoming investor conferences.

Nature's Sunshine Products, Inc. (Nasdaq:NATR)
, a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal care products, today reported its consolidated financial results for the third quarter ended September 30, 2013 and declared a regular quarterly cash dividend of $0.10 per share.

NewLink Genetics Corporation (NASDAQ: NLNK)
, a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced today that Charles J. Link, Jr., M.D., NewLink's Founder and Chief Executive Officer, is scheduled to present at the Credit Suisse 2013 Healthcare Conference in Phoenix, Arizona on Tuesday, November 12, 2013 at 5:00 p.m. ET.

NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY)
, a clinical-stage biopharmaceutical company developing non-antibiotic antimicrobial products, today announced that the auriclosene Phase 2b clinical study of impetigo has been completed.

Ocera Therapeutics, Inc. (Nasdaq:OCRX)
, a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today that it has obtained commitments to purchase common stock and warrants in a private placement.

Orexigen® Therapeutics, Inc. (Nasdaq: OREX)
, a biopharmaceutical company focused on the treatment of obesity, today announced that it has entered into a commercial supply agreement with Sanofi to act as Orexigen's contract manufacturer for Contrave® (32 mg naltrexone sustained release (SR) / 360 mg bupropion SR) for territories outside North America.  

Premier, Inc. (Nasdaq:PINC)
employees provided 3,000 hours of service to local organizations in the Charlotte area on Tuesday.

Repligen Corporation (Nasdaq:RGEN)
today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Stephens Fall Investment Conference on Wednesday, November 13 at 10:00 a.m. EST.

Response Biomedical Corp. (TSX:RBM) (OTCBB:RPBIF)
will release its third quarter 2013 financial results after the markets close on Wednesday, November 13, 2013.

SIGA Technologies, Inc. (Nasdaq:SIGA)
today reported its financial results for the three and nine months ended September 30, 2013.

Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS)
today announced that Daniel Swisher, Chief Executive Officer and President of Sunesis, will be presenting at the 2013 Credit Suisse Annual Health Care Conference on Wednesday, November 13th at 10:00 AM Mountain Time at The Phoenician Hotel in Scottsdale, Arizona.

Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN)
, a specialty pharmaceutical company, today announced that new clinical data will be released at the American Epilepsy Society (AES) Meeting this coming December in Washington DC.

TearLab Corporation (Nasdaq:TEAR) (TSX:TLB)
announced today that its Chief Executive Officer, Elias Vamvakas, will present an update on the Company's business at the Stephens Fall Investment Conference on Wednesday, November 13 at 11:00 a.m. Eastern Time.  

Vical Incorporated (Nasdaq:VICL)
today announced that the company will provide an overview of its technologies, development programs, and strategic partnerships on Wednesday, November 13, at 4:00 p.m. MT/6:00 p.m. ET at the 2013 Credit Suisse Healthcare Conference (Phoenix, AZ – November 11-14).

Vision-Sciences, Inc. (Nasdaq:VSCI)
announced today the publication of positive outcomes of a clinical study that evaluated the durability and microbial barrier properties of the Company's EndoSheath® technology in the flexible cystoscopy setting in the November issue of the peer-reviewed journal BMC Urology.

Vitacost.com, Inc. (Nasdaq:VITC)
, a leading online retailer of healthy living products, today reported financial results for the third quarter ended September 30, 2013.

XOMA Corporation (Nasdaq:XOMA)
, a leader in the discovery and development of therapeutic antibodies, announced today John Varian, the company's Chief Executive Officer, is scheduled to present at the 2013 Credit Suisse Healthcare Conference on November 13, 2013 at 1:00 p.m. MST, at the Phoenician Hotel in Scottsdale, Arizona.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter